|
시장보고서
상품코드
2091774
산필리포 증후군 시장 규모, 점유율 및 성장 분석 : 질환 서브타입별, 치료법별, 진단 방법별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Sanfilippo Syndrome Market Size, Share, and Growth Analysis, By Disease Subtype, By Treatment Type, By Diagnosis Method, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 산필리포 증후군 시장 규모는 2024년에 87억 8,000만 달러로 평가되며, 2025년 97억 달러에서 2033년까지 215억 6,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 10.5%로 성장할 것으로 전망되고 있습니다.
전 세계 산필리포 증후군 시장에서는 4가지 아형에 대한 진단 툴, 효소 보충 요법 및 유전자 편집 기술의 발전에 초점이 맞춰져 있습니다. 이 질환은 급속한 신경 퇴행을 동반하므로 효과적인 치료법의 확립이 시급한 과제로 대두되고 있으며, 이로 인해 전 세계 의료 시스템에 부담이 가중되고 있습니다. 과거에는 대증요법에만 중점을 두었으나, 효소 보충 요법의 도입으로 시장이 크게 발전했으며, 연구개발에 대한 투자도 증가하고 있습니다. 주요 동향으로는 특히 효소 결핍을 교정하는 바이러스 벡터 전달 시스템의 성공을 통해 유전자 치료의 상용화가 이루어진 점을 들 수 있습니다. 이는 투자자들로부터 큰 관심을 끌었으며, 주요 지역의 생산 능력 강화, 치료비 절감, 그리고 환자의 접근성 향상에 기여하는 업계 간 협력을 촉진했습니다. 그 결과, 건강보험사들은 혁신적인 임상시험 단계의 치료법을 인정하고 그 비용을 보상하기 시작했으며, 이를 통해 파이프라인의 다각화라는 선순환이 형성되어 시장의 지속적인 성장이 촉진되고 있습니다.
전 세계 산필리포 증후군 시장의 성장 요인
전 세계 산필리포 증후군 시장은 의료 종사자들 사이에서 이 질환에 대한 인식이 높아짐에 힘입어 눈에 띄게 성장하고 있습니다. 임상의들이 산필리포 증후군의 초기 증상을 정확히 파악하는 능력이 향상됨에 따라 유전자 검사와 적절한 치료를 위한 신속한 의뢰가 이루어질 가능성이 높아지고 있습니다. 이러한 인식의 확산은 가족들이 전문적인 서비스를 찾도록 유도할 뿐만 아니라, 진단 툴, 치료 연구 및 환자 관리 프로그램에 대한 수요도 높이고 있습니다. 또한 전문 학회의 교육 과정에 희귀질환에 관한 교육이 포함됨에 따라 의뢰 네트워크가 강화되고 다직종 팀 간의 협력이 촉진되어 전 세계 시장 전체의 성장에 크게 기여하고 있습니다.
세계 산필리포 증후군 시장의 제약 요인
전 세계 산필리포 증후군 시장의 성장을 가로막는 주요 장애물은 진단 검사의 이용 가능성이 제한적이라는 점이며, 이로 인해 각 지역에서 이 질환의 조기 발견이 저해되고 있습니다. 이러한 접근성 부족은 종종 치료 개입의 지연이나 임상 프로그램의 환자 등록자 수 감소로 이어집니다. 검사 인프라의 미비함은 정확한 진단에 대한 의료 종사자들의 신뢰를 저해할 가능성이 있으며, 그 결과 치료 선택지 및 지원 서비스에 대한 수요가 더욱 감소하게 됩니다. 그 결과, 이러한 상황은 조사 목적상 필수적인 데이터 수집을 방해하고, 전문 검사실에 대한 투자를 저해하며, 표적 치료 전략보다는 대증 요법에 대한 의존을 장기화시켜, 결국 시장의 발전을 지연시키게 됩니다.
전 세계 산필리포 증후군 시장의 동향
전 세계 산필리포 증후군 시장에서는 혁신적인 유전자 치료법의 등장으로 인해 획기적인 변화가 나타나고 있습니다. CRISPR나 베이스 에디팅과 같은 최첨단 플랫폼은 단순히 증상을 관리하는 데 그치지 않고, 질병의 근본 원인을 해결함으로써 치료법 개발에 혁명을 일으키고 있습니다. 생명공학 기업과 학술기관 간의 공동 연구를 통해 적응형 접근 방식을 촉진하는 지원적인 규제 환경의 지원도 받으며, 전임상 연구가 가속화되고 있습니다. 이러한 역동적인 환경은 투자자들의 신뢰를 높이고, 잠재적인 치료법 파이프라인을 확대하며, 유전자 치료가 획기적인 질환 수정 요법으로 부상할 수 있는 길을 열어가고 있습니다. 이로 인해 전 세계 치료 패러다임과 시장 상황이 크게 변화할 가능성이 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 산필리포 증후군 시장 규모 : 질환 서브타입별
세계의 산필리포 증후군 시장 규모 : 치료 유형별
세계의 산필리포 증후군 시장 규모 : 진단 방법별
세계의 산필리포 증후군 시장 규모 : 유통 채널별
세계의 산필리포 증후군 시장 규모 : 최종사용자별
세계의 산필리포 증후군 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Sanfilippo Syndrome Market size was valued at USD 8.78 Billion in 2024 and is poised to grow from USD 9.7 Billion in 2025 to USD 21.56 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).
The global Sanfilippo Syndrome market is focused on advancing diagnostic tools, enzyme-replacement therapies, and gene-editing technologies for its four sub-types. The urgency for effective treatments is driven by the condition's rapid neurodegeneration, which strains healthcare systems globally. Once centered solely on supportive care, the market has evolved significantly with the introduction of enzyme-replacement therapies, leading to increased investment in research and development. Key trends highlight gene therapy commercialization, particularly through successful viral-vector delivery systems that rectify enzymatic deficiencies. This attracted substantial investor interest, spurring industry partnerships that enhance manufacturing, lower treatment costs, and improve patient access in key regions. Consequently, health insurers are starting to recognize and cover innovative trial-based treatments, fostering a cycle of pipeline diversification and promoting sustained market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sanfilippo Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Sanfilippo Syndrome Market Segments Analysis
Global sanfilippo syndrome market is segmented by disease subtype, treatment type, diagnosis method, distribution channel, end user and region. Based on disease subtype, the market is segmented into MPS IIIA (Sanfilippo A), MPS IIIB (Sanfilippo B), MPS IIIC (Sanfilippo C) and MPS IIID (Sanfilippo D). Based on treatment type, the market is segmented into gene therapy, enzyme replacement therapy (ERT), substrate reduction therapy, stem cell therapy and supportive care. Based on diagnosis method, the market is segmented into GAG (glycosaminoglycan) analysis, genetic testing and enzyme assay. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics and research centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Sanfilippo Syndrome Market
The global Sanfilippo Syndrome market is witnessing considerable expansion driven by the growing awareness among healthcare professionals. As clinicians become increasingly adept at identifying the early symptoms of Sanfilippo Syndrome, they are more likely to initiate prompt referrals for genetic testing and appropriate care. This increased awareness not only encourages families to pursue specialized services but also boosts the demand for diagnostic tools, therapeutic research, and patient management programs. Moreover, the integration of rare disease education into professional society curricula enhances referral networks, promotes collaboration among multidisciplinary teams, and significantly contributes to the overall growth of the market on a global scale.
Restraints in the Global Sanfilippo Syndrome Market
A significant barrier to the growth of the Global Sanfilippo Syndrome market is the limited availability of diagnostic tests, which hampers the early identification of the condition in various regions. This lack of accessibility often results in delayed interventions and fewer patients enrolling in clinical programs. Inadequate testing infrastructure can lead to a deficit of confidence among healthcare providers regarding accurate diagnoses, further diminishing demand for therapeutic options and supportive services. Consequently, this situation impedes essential data collection for research purposes, discourages investment in specialized laboratories, and perpetuates a reliance on symptomatic management over targeted treatment strategies, ultimately slowing market progress.
Market Trends of the Global Sanfilippo Syndrome Market
The Global Sanfilippo Syndrome market is witnessing a transformative trend driven by the advent of innovative gene therapies. Cutting-edge platforms like CRISPR and base-editing are revolutionizing therapeutic development by addressing the root causes of the disease, rather than merely managing symptoms. Collaborative efforts between biotech firms and academic institutions are expediting preclinical research, bolstered by a supportive regulatory landscape that promotes adaptive approaches. This dynamic environment is enhancing investor confidence, broadening the pipeline of potential treatments, and paving the way for gene therapy to emerge as a groundbreaking, disease-modifying option that could significantly alter treatment paradigms and market landscapes globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Sanfilippo Syndrome Market Size by Disease Subtype & CAGR (2026-2033)
- Market Overview
- MPS IIIA (Sanfilippo A)
- MPS IIIB (Sanfilippo B)
- MPS IIIC (Sanfilippo C)
- MPS IIID (Sanfilippo D)
Global Sanfilippo Syndrome Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Gene Therapy
- Enzyme Replacement Therapy (ERT)
- Substrate Reduction Therapy
- Stem Cell Therapy
- Supportive Care
Global Sanfilippo Syndrome Market Size by Diagnosis Method & CAGR (2026-2033)
- Market Overview
- GAG (Glycosaminoglycan) Analysis
- Genetic Testing
- Enzyme Assay
Global Sanfilippo Syndrome Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
Global Sanfilippo Syndrome Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Research Centers
Global Sanfilippo Syndrome Market Size & CAGR (2026-2033)
- North America (Disease Subtype, Treatment Type, Diagnosis Method, Distribution Channel, End User)
- US
- Canada
- Europe (Disease Subtype, Treatment Type, Diagnosis Method, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Subtype, Treatment Type, Diagnosis Method, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Subtype, Treatment Type, Diagnosis Method, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Subtype, Treatment Type, Diagnosis Method, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMarin Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- JCR Pharmaceuticals Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Denali Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- REGENXBIO Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orchard Therapeutics PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abeona Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurogene Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taysha Gene Therapies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MeiraGTx Holdings PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sangamo Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lysogene SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Spark Therapeutics, Inc. (Roche)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PTC Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Spruce Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sio Gene Therapies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ArmaGen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allievex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LogicBio Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
